<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> comprise a poor-risk subset of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Large-scale mutation profiling efforts in de novo <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> have identified mutations that correlate with clinical features, but such mutations have not been investigated in therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Genomic DNA from 38 patient samples were subjected to high throughput polymerase chain reaction and sequenced for TP53, TET2, DNMT3A, ASXL1, IDH1, IDH2, EZH2, EED, SUZ12, RBBP4, SRSF2, U2AF35, and SF3B1 </plain></SENT>
<SENT sid="3" pm="."><plain>We identified <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in 16 of 38 (42%) patients </plain></SENT>
<SENT sid="4" pm="."><plain>TP53 mutations were the most common lesion, detected in 8 of 38 (21%) patients, followed by TET2 in 4 of 38 (10.5%) </plain></SENT>
<SENT sid="5" pm="."><plain>Cases with a TP53 mutation or loss of the TP53 locus had a worse overall survival compared to those with <z:mp ids='MP_0002169'>wild-type</z:mp> TP53 (8.8 vs. 37.4 months; P=0.0035) </plain></SENT>
</text></document>